Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor.

<bold>Background: </bold>Vascular endothelial growth factor (VEGF) promotes angiogenesis and vascular permeability. The extent to which VEGF may cause tissue edema in humans has not been established.<bold>Objective: </bold>To evaluate patients undergoing VEGF gene transfer for evidence of lower-extremity edema.<bold>Design: </bold>Prospective consecutive case series.<bold>Setting: </bold>Hospital outpatient clinic.<bold>Patients: </bold>62 patients with critical limb ischemia and 28 patients with claudication.<bold>Intervention: </bold>Gene transfer of VEGF DNA.<bold>Measurements: </bold>Semiquantitative analysis of lower-extremity edema.<bold>Results: </bold>Lower-extremity edema was observed in 31 of 90 (34%) patients. Edema was less common in patients with claudication than in those with pain at rest (P = 0.016) or ischemic ulcers (P < 0.001), and it was less common in patients with pain at rest than in those with ischemic ulcers (P= 0.017). Treatment was typically limited to a brief course of oral diuretics.<bold>Conclusions: </bold>Vascular endothelial growth factor may enhance vascular permeability in humans. At the doses of plasmid DNA used in this study, lower-extremity edema responded to oral diuretic therapy and did not seem to be associated with serious sequelae. [ABSTRACT FROM AUTHOR]